Insulin News and Research

RSS

Insulin is a hormone that is needed to convert glucose, starches and other food into energy needed for daily life. Insulin allows cells to use glucose for fuel and is secreted by beta cells in the islets of Langerhans. The release of insulin from the pancreas is stimulated by increased blood glucose, vagal nerve stimulation, and other factors. Insulin is obtained from various animals and available in a variety of preparations. Commercial insulin preparations differ in a number of ways, including differences in the animal species from which they are obtained; their purity, concentration, and solubility; and the time of onset and duration of their biologic action. An oral hypoglycemic agent is not a form of insulin therapy.

Study analyzes Rx purchasing habits of dLife members prior to and after engaging with dLife

A new study analyzing patient-level prescription data clearly demonstrates that dLife consumers take immediate and deeper action in treating their diabetes and co-morbid conditions after becoming engaged with dLife. The study also confirms that dLife users test their blood sugar and take medications at a higher rate than non-dLife users.

4 Mar 2010

St. Jude Medical publishes clinical results of HOMEOSTASIS trial

St. Jude Medical, Inc. today announced publication of clinical results in the Hemodynamically Guided Home Self-Therapy in Severe Heart Failure Patients (HOMEOSTASIS) trial.

4 Mar 2010

Study suggests vitamin D supplements may decrease insulin resistance, fight depression

A daily dose of vitamin D may just be what Chicagoans need to get through the long winter, according to researchers at Loyola University Chicago Marcella Niehoff School of Nursing (MNSON). This nutrient lifts mood during cold weather months when days are short and more time is spent indoors.

4 Mar 2010

CPEX Pharmaceuticals' fourth-quarter 2009 revenues up 23%

CPEX Pharmaceuticals, Inc. today reported financial results for the fourth quarter and year ended December 31, 2009. For the quarter CPEX reported revenues of $5.2 million and a net loss of $498,000. For the year CPEX reported revenues of $18.7 million and a net loss of $3.0 million.

3 Mar 2010

VUCCC files for patent protection: New treatment regimen for Type 1 insulin-dependent diabetes

VUCCC P/L is pleased to announce that it has filed for patent protection of its ground breaking new treatment regimen for Type 1 'insulin-dependent' diabetes, through the European Patent Office.

3 Mar 2010

Diabetics at risk: Nova Scotia limits pharmacare coverage of blood glucose test strips

The Nova Scotia government's decision to limit Pharmacare coverage of blood glucose test strips for some diabetes patients places a significant financial and health burden on these Nova Scotians and violates the fundamental principle that patients and their healthcare professionals should be able to determine how to manage treatment.

3 Mar 2010

Patient Safety Authority highlights analysis of data related to insulin medication errors

Pennsylvania healthcare facilities submitted over 2,600 event reports that involved the use of insulin products to the Patient Safety Authority where more than 52 percent led to situations in which a patient may have or actually received the wrong dose or no dose of insulin. The data raises awareness of a broader issue that is highlighted in the 2010 March Pennsylvania Patient Safety Advisory.

3 Mar 2010

Common diabetes therapies may increase cancer risk, but more research needed

The benefits of using insulin to treat diabetes far outweigh the risks, but a review just published online by IJCP, the International Journal of Clinical Practice, suggests that commonly used diabetes therapies may differ from each other when it comes to their influence on cancer risk.

3 Mar 2010

Novo Nordisk awarded contract by VA as primary source provider of insulin

Novo Nordisk, a global healthcare company and leader in diabetes care, announced it has been awarded a contract by the U.S. Department of Veterans Affairs as the primary source provider of insulin. The one year contract began on March 1, 2010 and the VA has the option to renew the contract annually for up to an additional four years.

From Novo Nordisk 3 Mar 2010

Pioneering stem cell research could revolutionize treatments for diabetes and Alzheimer's disease

A heart patient's own skin cells soon could be used to repair damaged cardiac tissue thanks to pioneering stem cell research of the University of Houston's newest biomedical scientist, Robert Schwartz.

3 Mar 2010

Not getting enough sleep can cause fat to accumulate around organs, say researchers

Not getting enough sleep does more damage than just leaving you with puffy eyes. It can cause fat to accumulate around your organs - more dangerous, researchers say, than those pesky love handles and jiggly thighs.

2 Mar 2010

Future work may uncover links between insulin use and cancer risk, say researchers

2 Mar 2010

High levels of anti-aging hormone may increase cancer mortality in older men

According to a new study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM), older men with high levels of the hormone IGF-I (insulin-like growth factor 1) are at increased risk of cancer death, independent of age, lifestyle and cancer history.

2 Mar 2010

Biodel seeks FDA marketing approval for VIAject

Biodel Inc. announced today that the U.S. Food and Drug Administration has accepted for review the company’s new drug application (NDA) seeking approval to market VIAject® for the treatment of diabetes. VIAject® is Biodel's proprietary formulation of recombinant human insulin that is designed to be absorbed into the blood faster than currently marketed rapid-acting insulin analogs.

1 Mar 2010

Using genetic engineering techniques in pigs, scientists create new model of diabetes

The incidence of diabetes is rising worldwide. Using genetic engineering techniques in pigs, scientists at Ludwig-Maximilians-Universität in Munich have created a new model of this metabolic disorder, which recapitulates many features of the disease, and promises to contribute significantly to improvements in diagnosis and therapy.

1 Mar 2010

Inadequate sleep may lead to increase in belly fat

A study in the March 1 issue of the journal SLEEP shows that African-American and Hispanic young adults with short or long sleep durations had greater increases in belly fat over a five-year period compared with those who reported sleeping six to seven hours a night.

1 Mar 2010

Ipsen’s 2009 performance: Azzalure, Dysport and Decapeptyl approval, Adenuric partnership, drug sales up 7.6%

The Board of Directors of Ipsen, chaired by Jean-Luc Bélingard, met on 26 February 2010 to review the Group’s results for 2009, published today.

1 Mar 2010

Over 16% of pregnant women diagnosed with gestational diabetes

Two to three times more pregnant women may soon be diagnosed and treated for gestational diabetes, based on new measurements for determining risky blood sugar levels for the mother and her unborn baby, according to a study that was coordinated by investigators at Northwestern University Feinberg School of Medicine.

26 Feb 2010

Semafore Pharmaceuticals awarded U.S. patent covering PI-3 kinase inhibitor prodrugs

Semafore Pharmaceuticals today announced today announced the United States Patent and Trademark Office (PTO) has issued United States Patent Number 7,662,977 entitled “PI-3 Kinase Inhibitor Prodrugs.” This composition of matter patent covers a genus of novel compounds that includes SF1126, Semafore’s clinical stage, small molecule inhibitor of phosphoinositide-3-kinase (PI3K) and mammalian target of rapamycin (mTOR), two key members of the PI3K signaling pathway that is vital to several essential biological processes, such as cell proliferation and survival.

25 Feb 2010

Study examines how individuals utilize benefits and services under Medicare program

Findings released today and detailed in the analysis Low Consumption and Higher Medicare Cost: Consumption Clusters in a Medicare Fee-for-Service Population, examine how individuals utilize benefits and services under the Medicare program.

25 Feb 2010

Insulin News and Research

Further Reading

Study analyzes Rx purchasing habits of dLife members prior to and after engaging with dLife

St. Jude Medical publishes clinical results of HOMEOSTASIS trial

Study suggests vitamin D supplements may decrease insulin resistance, fight depression

CPEX Pharmaceuticals' fourth-quarter 2009 revenues up 23%

VUCCC files for patent protection: New treatment regimen for Type 1 insulin-dependent diabetes

Diabetics at risk: Nova Scotia limits pharmacare coverage of blood glucose test strips

Patient Safety Authority highlights analysis of data related to insulin medication errors

Common diabetes therapies may increase cancer risk, but more research needed

Novo Nordisk awarded contract by VA as primary source provider of insulin

Pioneering stem cell research could revolutionize treatments for diabetes and Alzheimer's disease

Not getting enough sleep can cause fat to accumulate around organs, say researchers

Future work may uncover links between insulin use and cancer risk, say researchers

High levels of anti-aging hormone may increase cancer mortality in older men

Biodel seeks FDA marketing approval for VIAject

Using genetic engineering techniques in pigs, scientists create new model of diabetes

Inadequate sleep may lead to increase in belly fat

Ipsen’s 2009 performance: Azzalure, Dysport and Decapeptyl approval, Adenuric partnership, drug sales up 7.6%

Over 16% of pregnant women diagnosed with gestational diabetes

Semafore Pharmaceuticals awarded U.S. patent covering PI-3 kinase inhibitor prodrugs

Study examines how individuals utilize benefits and services under Medicare program

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News